139501-62-5

Upstream product

• 149810-21-9 5-butyl-2,4-dihydro-4-<<2-<1-(triphenylmethyl)-1H-tetrazol-5-yl><1,1'-biphenyl>-4'-yl>methyl>-3H-1,2,4-triazol-3-one 
• 133690-80-9 5-butyl-2,4-dihydro-4-<<2'-(1H-tetrazol-5-yl)<1,1'-biphenyl>-4-yl>methyl>-3H-1,2,4-triazol-3-one 
• 133726-98-4 5-n-Butyl-2,4-dihydro-4-[[2'-cyanobiphenyl-4-yl]methyl]-3H-1,2,4-triazol-3-one 
• 149810-18-4 2-cyano-4'-<<<<2-(1-oxopentyl)hydrazino>carbonyl>amino>methyl>-1,1'-biphenyl 
• 133690-91-2 4'-(azidomethyl)[1,1'-biphenyl]-2-carbonitrile 
• 133690-92-3 [(2'-cyanobiphenyl-4-yl)methyl]amine 
• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 114772-53-1 2-Cyano-4'-methylbiphenyl 

Relevant academic research and scientific papers

Synthesis and Structure-Activity Relationships of Nonpeptide, Potent Triazolone-Based Angiotensin II Receptor Antagonists

2,5-Dibutyl-2,4-dihydro-4--4'-yl>methyl>-3H-1,2,4-triazol-3-one, SC-51316, was synthesized as a potent and orally active angiotensin II (AII) receptor antagonist with a long duration of action.To explore the lipophilic pocket in the AII receptor interacting with the substituent at the 2-position of triazolone-based antagonists, a series of compounds were prepared and evaluated for receptor binding affinity and antagonism of AII-contracted rabbitaortic rings.It has been found that the pocket is very spacious and can accommodate different sizes of lipophilic groups and various functionalities.Acidic groups generally result in a slight decrease in binding affinity.Branched chains are unfavorable.The freedom of rotation around C2-C3 in the flexible side chain is crucial for good binding.The 2-phenylethyl-substituted triazolone analogue exhibits the highest in vitro potency among all compounds that have been synthesized.